Induced Pluripotent Stem Cell-Derived Natural Killer Cells for Treatment of Ovarian Cancer

Stem Cells

Volumn 34, Issue 1, 2016, Pages 93-101

  Hermanson, David L ^a   Bendzick, Laura ^a   Pribyl, Lee ^b   McCullar, Valarie ^a   Vogel, Rachel Isaksson ^c   Miller, Jeff S ^a   Geller, Melissa A ^b   Kaufman, Dan S ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Immunotherapy; Induced pluripotent stem cells; Natural killer cells; Ovarian cancer

Indexed keywords

ANIMAL; BLOOD; CELL PROLIFERATION; CYTOLOGY; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOTHERAPY; INDUCED PLURIPOTENT STEM CELL; MOUSE; NATURAL KILLER CELL; OVARIAN NEOPLASMS; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOTHERAPY; INDUCED PLURIPOTENT STEM CELLS; KILLER CELLS, NATURAL; MICE; OVARIAN NEOPLASMS;

EID: 84954209229     PISSN: 10665099     EISSN: 15494918     Source Type: Journal    
DOI: 10.1002/stem.2230     Document Type: Article

References (24)

1. Armstrong DK,. Relapsed ovarian cancer: Challenges and management strategies for a chronic disease. Oncologist 2002; 7 (Suppl 5): 20-28.
2. Geller MA, Cooley S, Judson PL, et al., A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer. Cytotherapy 2011; 13: 98-107.
3. Miller JS, Soignier Y, Panoskaltsis-Mortari A, et al., Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 2005; 105: 3051-3057.
4. Geller MA, Knorr DA, Hermanson DA, et al., Intraperitoneal delivery of human natural killer cells for treatment of ovarian cancer in a mouse xenograft model. Cytotherapy 2013; 15: 1297-1306.
5. Koepsell SA, Miller JS, McKenna DH,. Natural killer cells: A review of manufacturing and clinical utility. Transfusion 2013; 53: 404-410.
6. Knorr DA, Ni Z, Hermanson D, et al., Clinical-scale derivation of natural killer cells from human pluripotent stem cells for cancer therapy. Stem Cells Transl Med 2013; 2: 274-283.
7. Eguizabal C, Zenarruzabeitia O, Monge J, et al., Natural killer cells for cancer immunotherapy: Pluripotent stem cells-derived NK cells as an immunotherapeutic perspective. Front Immunol 2014; 5: 439.
8. Ni Z, Knorr DA, Clouser CL, et al., Human pluripotent stem cells produce natural killer cells that mediate anti-HIV-1 activity by utilizing diverse cellular mechanisms. J Virol 2011; 85: 43-50.
9. Woll PS, Grzywacz B, Tian X, et al., Human embryonic stem cells differentiate into a homogeneous population of natural killer cells with potent in vivo antitumor activity. Blood 2009; 113: 6094-6101.
10. Kaufman DS, Hanson ET, Lewis RL, et al., Hematopoietic colony-forming cells derived from human embryonic stem cells. Proc Natl Acad Sci USA 2001; 98: 10716-10721.
11. Ng ES, Davis R, Stanley EG, et al., A protocol describing the use of a recombinant protein-based, animal product-free medium (APEL) for human embryonic stem cell differentiation as spin embryoid bodies. Nat Protoc 2008; 3: 768-776.
12. Denman CJ, Senyukov VV, Somanchi SS, et al., Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells. PLoS One 2012; 7: e30264.
13. Ljunggren HG, Malmberg KJ,. Prospects for the use of NK cells in immunotherapy of human cancer. Nat Rev Immunol 2007; 7: 329-339.
14. Yang XY, Zeng H, Chen FP,. Cytokine-induced killer cells: A novel immunotherapy strategy for leukemia. Oncol Lett 2015; 9: 535-541.
15. Bodduluru LN, Kasala ER, Madhana RM, et al., Natural killer cells: The journey from puzzles in biology to treatment of cancer. Cancer Lett 2015; 357: 454-467.
16. Cooley S, Weisdorf DJ, Guethlein LA, et al., Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia. Blood 2010; 116: 2411-2419.
17. Cooley S, Weisdorf DJ, Guethlein LA, et al., Donor killer cell Ig-like receptor B haplotypes, recipient HLA-C1, and HLA-C mismatch enhance the clinical benefit of unrelated transplantation for acute myelogenous leukemia. J Immunol 2014; 192: 4592-4600.
18. Impola U, Turpeinen H, Alakulppi N, et al., Donor haplotype B of NK KIR receptor reduces the relapse risk in HLA-identical sibling hematopoietic stem cell transplantation of AML patients. Front Immunol 2014; 5: 405.
19. Michaelis SU, Mezger M, Bornhäuser M, et al., KIR haplotype B donors but not KIR-ligand mismatch result in a reduced incidence of relapse after haploidentical transplantation using reduced intensity conditioning and CD3/CD19-depleted grafts. Ann Hematol 2014; 93: 1579-1586.
20. Oevermann L, Michaelis SU, Mezger M, et al., KIR B haplotype donors confer a reduced risk for relapse after haploidentical transplantation in children with ALL. Blood 2014; 124: 2744-2747.
21. Scales SJ, Gupta N, Pacheco G, et al., An antimesothelin-monomethyl auristatin e conjugate with potent antitumor activity in ovarian, pancreatic, and mesothelioma models. Mol Cancer Ther 2014; 13: 2630-2640.
22. Schwab CL, English DP, Roque DM, et al., Past, present and future targets for immunotherapy in ovarian cancer. Immunotherapy 2014; 6: 1279-1293.
23. Beatty GL, Haas AR, Maus MV, et al., Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. Cancer Immunol Res 2014; 2: 112-120.
24. Carpenito C, Milone MC, Hassan R, et al., Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc Natl Acad Sci USA 2009; 106: 3360-3365.